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EDITORIAL

Transplant oncology in locally advanced intrahepatic
cholangiocarcinoma: One more step on a long road
In the current issue of American Journal of Transplantation, McMillan

As acknowledged by the authors, one reflection of this is the lack

et al. analyze the survival after liver transplantation (LT) for patients

of racial and ethnic diversity. Another is the potential for system-

with locally advanced, unresectable, intrahepatic cholangiocarcinoma

atic bias regarding socioeconomic status and access to health care.

1,2

iCCA has long repre-

Consequently, these points call into question the generalizability of

sented a contraindication for LT due to historically poor results, largely

the findings, along with the potential for unmeasured and residual

driven by an absence of strict selection criteria and limited understand-

confounding. Moreover, the patient population and pre-LT treatment

ing of tumor biology. The re-appraisal of LT as a curative-treatment

strategies were heterogeneous (including various types of locore-

modality for iCCA has been catalyzed by favorable oncologic results

gional therapies, liver resection, and targeted therapies including

(iCCA), building upon their earlier experience.

in patients with iCCA discovered after LT in several single-and multi-

IDH-1-, FGFR-, and PARP-inhibition). Though there were no statis-

institutional studies.3 Many iCCA patients present with locally ad-

tically significant differences between the groups in the distribution

vanced disease that precludes resection, resulting in dismal outcomes.

of such treatments, possibly due to a small sample size, there may be

Available treatment options for these patients include systemic and

residual confounding with regards to the nuances in these therapies.

locoregional therapy—none of which have curative potential.

In addition, the range of time between diagnosis and listing was wide

In contrast to previous studies in the field, all patients in the study

(74–1054 days), suggesting variability in the ability to assess tumor

by Mcmillan et al. had an iCCA diagnosis before listing. Their iCCA LT

biology clinically. The pre-LT treatment heterogeneity is understand-

protocol is based on receipt of neoadjuvant therapy (with first-line

able given the rarity of these tumors and is also reflective of “real-life”

being gemcitabine-cisplatin4) and demonstration of disease stability

individualized treatment strategies. However, it somewhat opacifies

for at least six months (based on radiographic assessment). 2 To be

our understanding for which patients LT may come to represent a

included, patients could have any tumors confined to the liver in the

realistic option. Next-generation sequencing was performed for al-

absence of vascular or lymph node involvement. Over eleven years,

most all patients, but the patterns of genetic alterations did not dif-

65 patients were referred, of which 28 were denied transplant list-

fer between groups. Nevertheless, prior studies would suggest that

ing. Five patients listed became eligible for resection due to disease

patients with more favorable alternations will be better candidates

regression with neoadjuvant therapy and were excluded. Of the

for LT.5 The small study size limits the potential of performing a risk-

thirty-t wo patients included, eighteen underwent LT, and fourteen

factor analysis to identify factors associated with better or worse

did not. Seven patients dropped out due to disease progression. The

outcomes, including early recurrence. Therefore, it is imperative

intention-to-treat 1-, 3-, and 5-year survival was 90%, 61%, and 49%.

that future studies, ideally using multicenter designs, aim to amass

However, the exclusion of the five listed patients who underwent

a sufficient number of patients to yield adequate statistical power

resection may have led to an underestimation of the survival in the

to detect inter-group differences. Such differences can help refine

non-LT group. Patients able to undergo LT had better survival than

prognostication and improve treatment selection strategies. External

patients who did not (1-, 3-, and 5-year LT: 100%, 71%, 57% vs. 1-

validation of these results with well-defined neoadjuvant protocols

year non-LT 71%;p = 0.004), though this comparison is susceptible

will be essential in the effort to standardize this as a treatment option

to selection bias. Notably, the recurrence-free survival at 3-years

for a subset of iCCA patients. Several potential strategies can be con-

was 52%, with seven of the eighteen patients transplanted develop-

sidered for refining future iCCA liver transplant protocols (Table 1).

ing recurrence (four of which recurred within the first year).

Finally, we must be mindful of which patients should represent the

The authors should be commended for pushing the envelope in

comparison group for iCCA patients considered/listed for LT as the

transplant oncology and helping move the needle in this realm. This

other treatment options are non-curative. Despite several challenges

progress has been afforded by way of a well-developed protocol and

to performing randomized controlled trials in transplant oncology,

a highly experienced multi-disciplinary team effort. As in any study,

there should be a global effort in that direction.6 The authors should

some limitations should be acknowledged, as building upon these

be congratulated on their efforts in the transplant oncology domain.

will support future efforts in understanding the role of LT for iCCA.

Their study shows that, while LT is not the panacea for all iCCA pa-

Patients included in the study represented a highly selected group.

tients, it can represent the much-needed beacon of hope for some.
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TA B L E 1 Potential strategies for refining future iCCA liver
transplant protocols
Strategy

Example

Identification
of genetic
determinants
that portend
a better
or worse
prognosis

-	 A recent bi-institutional study of unresectable
iCCA patients identified specific genetic
determinants, such as TP53, KRAS, and
cyclin-dependent kinase inhibitor 2a
(CDKN2A), to portend a worse prognosis.6

Clarifying the
static and
dynamic role
of biomarkers
such as CA
19-9

-	 Elevated CA19-9 is a risk factor for mortality
in iCCA similar in impact to nodal metastases
and positive resection margins.7

The use of new
innovative
technologies

-	 Radiomics, a field of imaging-based research
that can extract data from imaging and be
used as an imaging-based biomarker, can
also possibly improve the characterization of
more indolent disease.
-	 Machine learning technology can be
leveraged to identify favorable and
unfavorable disease phenotypes based on all
available clinical, genetic, and radiographic
information.

Novel therapies

-	 Targeted therapies, such as FGFR-inhbition
for iCCA with FGFR2 fusion.8
-	 The addition of immune checkpoint inhibition
to chemotherapy has shown early promise
and potential benefit compared to standard-
of-care chemotherapy (gemcitabine-cisplatin)
and may help more patients reach the point
of being considered for LT in the setting of
ongoing and future trials.9

cancer/malignancy/neoplasia, clinical research/practice, liver
disease: malignant, liver transplantation/hepatology,
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